|Description||MLN1117, also known as INK1117, is a PI3Kα inhibitor which could lead to the apoptosis and growth retardation of tumor cells expressed by PI3Kα. IC50: 15 nM.|
|Synonyms||INK1117; INK-1117; INK 1117; MLN1117; MLN 1117; MLN-1117; TAK-117; TAK 117; TAK117; Serabelisib; [6-(2-amino-1,3-benzoxazol-5-yl)imidazo[1,2-a]pyridin-3-yl]-morpholin-4-ylmethanone;Serabelisib|
|Solubility||DMSO: ≥ 6.4 mg/mL (Need ultrasonic or warming)|
|Application||MLN1117 is a PI3Kα inhibitor which could lead to the apoptosis and growth retardation of tumor cells expressed by PI3Kα.|
|Shelf Life||As supplied, 2 years from the QC date provided on the Certificate of Analysis, when stored properly|
A selective class I PI3K inhibitor; it inhibits PI3K p110 isoforms, mTOC1 and also DNA-PK; a valuable tool compound
PIK-93 is a potent PI3K inhibitor.
NVP-BBD130 is a potent and selective dual PI3K/mTOR inhibitor. It can suppress the growth and proliferation of melanoma primary tumors and metastasis via inhibi...
CAL-130 is a potent and selective PI3K gamma and delta inhibitor with potential anticancer activity. Constitutive phosphoinositide 3-kinase (PI3K)/Akt activatio...
PI3Ky inhibitor 1
PI3Ky inhibitor 1 is a potent PI3Ky inhibitor.
eCF309 is a potent and cell-permeable inhibitor of mTOR signaling (IC50 value 10 - 15 nM in vitro and in vivo) that exhibits >60-fold selectivity over PI3Ks. It...
PDK1 inhibitor 2610 is an ATP-competitive and selective dual PI3K and PDPK1 inhibitor (IC50 values 34 nM and 94 nM for PDK1 and p-T308-PKB, respectively).
Taselisib, also known as GDC0032 or RG7606, is a selective, potent, orally bioavailable inhibitor of PI3Ka with a Ki = 0.2nM, and with reduced inhibitory activi...